

INPLASY PROTOCOL

To cite: Tang et al. Bone marrow mononuclear cell transplantation in patients with ischaemic stroke: protocol for a meta-analysis. Inplasy protocol 202340061. doi: 10.37766/inplasy2023.4.0061

Received: 18 April 2023

Published: 18 April 2023

Corresponding author:
Zhong Wang

wangzhong761@163.com

Author Affiliation: First affiliated hospital of Soochow University.

Support: The Natural Science Foundation of Jiangsu Province (Grants No BK20200203).

Review Stage at time of this submission: Preliminary searches.

Conflicts of interest:
None declared.

Bone marrow mononuclear cell transplantation in patients with ischaemic stroke: protocol for a meta-analysis

Tang, YB¹; Wang, ZL²; Teng, HY³; Ni, HY⁴; Chen, HR⁵; Lu, JY⁶; Chen, ZQ⁷; Wang, Z⁸.

Review question / Objective: To investigate the efficacy and safety of bone marrow mononuclear cell (BMMNCs) transplantation treatment of ischemic stroke (IS).

Condition being studied: To investigate the efficacy and safety of bone marrow mononuclear cell (BMMNCs) transplantation treatment of ischemic stroke (IS).

INPLASY registration number: This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 18 April 2023 and was last updated on 18 April 2023 (registration number INPLASY202340061).

INTRODUCTION

Review question / Objective: To investigate the efficacy and safety of bone marrow mononuclear cell (BMMNCs) transplantation treatment of ischemic stroke (IS).

Condition being studied: BMMNCs transplantation therapy is a potential treatment for IS. Several RCTs related to

BMMNCs transplantation for IS have been published, while the results are inconclusive.

METHODS

Participant or population: IS, aged over 18.

Intervention: BMMNCs transplantation treatment with conventional drug treatment.

Comparator: Conventional drug treatment or with a sham bone marrow harvest and a sham infusion procedure.

Study designs to be included: RCT.

Eligibility criteria: Review, letter, comment case reports or case series.

Information sources: MEDLINE, Embase, the Cochrane Library, and clinicalTrials.gov

Main outcome(s): mRS score and NIHSS score.

Quality assessment / Risk of bias analysis: The risk of bias were assessed with Cochrane Collaboration tool.

Strategy of data synthesis: Data was analysed by Review Manager 5.3. Risk ratio was analyzed with 95% confidence intervals. $P \leq 0.05$ was statistically significant.

Subgroup analysis: The dosage and route of administration of BMSCs.

Sensitivity analysis: Cochrane's Q test and I² were used to explore heterogeneity.

Country(ies) involved: China.

Keywords: Ischemic stroke, randomized control trial, stem cells, stem cell therapy.

Contributions of each author:

Author 1 - Yanbing Tang.

Email: tangyb02@163.com

Author 2 - Zilan Wang.

Author 3 - Haiying Teng.

Author 4 - Huiru Chen.

Author 5 - Jiaye Lu.

Author 6 - Zhouqing Chen.

Author 7 - Zhong Wang.